Evidence map›Paper›PMID 35047068›Full record

ArticleEcancermedicalscience2021

Clinico-pathological relationship between androgen receptor and tumour infiltrating lymphocytes in triple negative breast cancer.

Hagar Elghazawy, Joaira Bakkach, Thanaa Helal, Ahmed M Aref, Mohamed Kelany, Lamiaa E Abdallah, Fatma S Abdelbakey, Dalia Ali, Doaa Z Ali, Mai O Ahmed and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Ecancermedicalscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Diverse role of androgen action in human breast cancer.Endocrine oncology (Bristol, England) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Hagar ElghazawyDepartment of Clinical Oncology, Faculty of Medicine, Ain Shams University, Cairo, 11591, Egypt.
Joaira BakkachBiomedical Genomics & Oncogenetics Research Laboratory, Faculty of Sciences and Techniques of Tangier, Abdelmalek Essaadi University, Tangier, 90 000, Morocco.
Thanaa HelalDepartment of Pathology, Faculty of Medicine, Ain Shams University, Cairo, 11591, Egypt.
Ahmed M ArefFaculty of Biotechnology, October University for Modern Sciences and Arts (MSA), Giza, 12451, Egypt.
Mohamed KelanyDepartment of Clinical Oncology, Faculty of Medicine, Ain Shams University, Cairo, 11591, Egypt.
Lamiaa E AbdallahDepartment of Clinical Oncology, Faculty of Medicine, Ain Shams University, Cairo, 11591, Egypt.
Fatma S AbdelbakeyDepartment of Clinical Oncology, Electricity Hospital, Cairo, 11775, Egypt.
Dalia AliDepartment of Clinical Oncology, Faculty of Medicine, Ain Shams University, Cairo, 11591, Egypt.
Doaa Z AliFaculty of Biotechnology, October University for Modern Sciences and Arts (MSA), Giza, 12451, Egypt.
Mai O AhmedFaculty of Biotechnology, October University for Modern Sciences and Arts (MSA), Giza, 12451, Egypt.
Amer Ali Abd El-HafeezPharmacology and Experimental Oncology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, 11796, Egypt.
Pradipta GhoshDepartment of Cellular and Molecular Medicine, School of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
Mohamed O AlorabiDepartment of Clinical Oncology, Faculty of Medicine, Ain Shams University, Cairo, 11591, Egypt.

Funding

Spatial Regulation of RGS and G Protein SignalingR01CA100768 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GHOSH, PRADIPTA · 2003 to 2019
$7.4M
Integrators of Metastatic PotentialR01CA238042 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GHOSH, PRADIPTA, LUKER, GARY D · 2019 to 2023
$2.3M
Modulation of G proteins by Growth FactorsR01CA160911 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GHOSH, PRADIPTA · 2013 to 2017
$1.8M
NCI NIH HHS R01 CA100768NCI NIH HHS R01 CA160911NCI NIH HHS R01 CA238042
6 · The paper itself

Abstract

backgroundTriple negative breast cancer (TNBC) is an aggressive subtype of breast cancer (BC) with ill-defined therapeutic targets. Androgen receptor (AR) and tumour-infiltrating lymphocytes (TILs) had a prognostic and predictive value in TNBC. The relationship between AR, TILs and clinical behaviour is still not fully understood.

methodsThirty-six TNBC patients were evaluated for AR (positive if ≥1% expression), CD3, CD4, CD8 and CD20 by immunohistochemistry. Stromal TILs were quantified following TILs Working Group recommendations. Lymphocyte-predominant breast cancer (LPBC) was defined as stromal TILs ≥ 50%, whereas lymphocyte-deficient breast cancer (LDBC) was defined as <50%.

resultsThe mean age was 52.5 years and 27.8% were ≥60 years. Seven patients (21.2%) were AR+. All AR+ cases were postmenopausal (≥50 years old). LPBC was 32.2% of the whole cohort. Median TILs were 37.5% and 10% (

conclusionsAR expression was evident in older age (≥50 years). Median CD20 was higher in AR- TNBC, while mean CD3 was higher in AR+ tumours. LDBC was associated with higher risk of LN involvement. Larger studies are needed to focus on the clinical impact of the relation between AR and TILs in TNBC.

Indexed as

androgen receptorARTILsTNBCtriple negative breast cancertumour infiltrating lymphocytes

Identifiers

PMID35047068
PMCPMC8723750

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.